Share Price and Basic Stock Data
Last Updated: November 26, 2025, 6:15 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Suven Life Sciences Ltd operates in the pharmaceuticals sector, with its current share price standing at ₹177 and a market capitalization of ₹4,024 Cr. The company has seen a fluctuating sales trend over recent quarters. For instance, sales were reported at ₹4 Cr in both June 2022 and June 2023, but dropped to ₹3 Cr in December 2022 and March 2023. The annual sales figures have also shown a downward trajectory, declining from ₹521 Cr in March 2015 to just ₹14 Cr in March 2023. The trailing twelve months (TTM) sales are recorded at ₹6 Cr, indicating persistent challenges in revenue generation. The operating profit margin (OPM) has remained negative, with the latest figure for March 2025 standing at -2,487%. This consistent decline in revenues and profitability signals potential challenges in product demand and market competition, necessitating a comprehensive review of business strategies to enhance revenue stability.
Profitability and Efficiency Metrics
Suven Life Sciences’ profitability metrics present a concerning picture, with the company reporting a net profit of -₹161 Cr for the fiscal year ending March 2025. The earnings per share (EPS) stood at -₹7.37, reflecting ongoing operational losses. Operating profit has also been negative, declining from -₹14 Cr in March 2019 to -₹166 Cr in March 2025. The interest coverage ratio (ICR) is significantly low at -3323.53x, indicating that the company is unable to cover its interest obligations, which poses a financial risk. Return on equity (ROE) and return on capital employed (ROCE) are reported at 87.2% and 87.0%, respectively, which may be misleading due to the negative net profit. The cash conversion cycle (CCC) has increased to 73 days, suggesting inefficiencies in managing working capital. Overall, these metrics highlight severe profitability issues that need immediate attention to avoid further deterioration.
Balance Sheet Strength and Financial Ratios
The balance sheet of Suven Life Sciences reveals a relatively strong position in terms of borrowings, as the company reported zero borrowings as of March 2025. However, total liabilities have decreased from ₹389 Cr in March 2023 to ₹135 Cr in March 2025. Reserves have also significantly declined, from ₹354 Cr in March 2023 to ₹88 Cr in March 2025, indicating a depletion of retained earnings. The company’s book value per share has fallen sharply to ₹5.04, down from ₹12.38 in the previous year. The price-to-book value (P/BV) ratio is notably high at 22.48x, suggesting that the stock may be overvalued relative to its net assets. The current ratio stands at 3.21, indicating good short-term liquidity, but the high P/BV raises concerns about sustainable growth. Overall, while the balance sheet shows low debt levels, the decline in reserves and high valuation ratios may pose risks to long-term financial health.
Shareholding Pattern and Investor Confidence
Suven Life Sciences exhibits a concentrated shareholding structure, with promoters holding 67.36% of the equity as of the latest report. This level of promoter ownership can instill confidence among investors regarding management commitment. However, Foreign Institutional Investors (FIIs) have a minimal stake of 1.17%, and Domestic Institutional Investors (DIIs) hold 3.39%, which reflects limited institutional interest. The public shareholding stands at 28.07%, with a total of 64,921 shareholders. Over the past quarters, the number of shareholders has fluctuated, indicating some instability in investor confidence. The gradual reduction in public shareholding and low FII participation might suggest a lack of confidence in the company’s prospects. This situation warrants a closer examination of the company’s strategic direction and its efforts to attract broader institutional investment, which could enhance its market standing.
Outlook, Risks, and Final Insight
The outlook for Suven Life Sciences appears challenging, primarily due to its persistent financial losses and declining revenue streams. The significant negative operating profit and net profit margins highlight the urgent need for operational restructuring and strategic realignment. Potential risks include the inability to improve sales, which could further erode investor confidence, and the high P/BV ratio that might limit stock appreciation potential. Conversely, the absence of debt provides a cushion against financial distress, and the promoter’s substantial stake could support long-term stability. The company must focus on enhancing operational efficiencies, exploring new revenue streams, and possibly restructuring its product offerings to regain market traction. If successful, Suven may stabilize its financial position and restore investor confidence, but failure to address these issues might lead to continued declines in performance.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Suven Life Sciences Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 162 Cr. | 129 | 247/84.3 | 35.9 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,538 Cr. | 417 | 479/192 | 94.0 | 24.3 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.9 Cr. | 47.0 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 41.5 Cr. | 28.3 | 29.1/17.0 | 98.8 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,356.00 Cr | 1,182.92 | 52.67 | 202.40 | 0.35% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 4 | 4 | 3 | 3 | 4 | 3 | 2 | 2 | 1 | 3 | 2 | 1 | 2 |
| Expenses | 25 | 26 | 55 | 34 | 32 | 27 | 49 | 33 | 32 | 55 | 41 | 45 | 53 |
| Operating Profit | -21 | -22 | -52 | -32 | -28 | -24 | -46 | -30 | -31 | -52 | -39 | -44 | -51 |
| OPM % | -596% | -494% | -1,719% | -1,208% | -737% | -768% | -1,885% | -1,267% | -3,024% | -2,032% | -2,435% | -2,981% | -2,714% |
| Other Income | 6 | 0 | 2 | 6 | 6 | 13 | 6 | 4 | 4 | 4 | 2 | 1 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 2 | 1 | 1 |
| Profit before tax | -16 | -23 | -51 | -28 | -24 | -13 | -42 | -28 | -28 | -50 | -39 | -44 | -52 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | -4% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | -16 | -23 | -51 | -28 | -24 | -13 | -42 | -27 | -28 | -50 | -39 | -44 | -52 |
| EPS in Rs | -0.75 | -1.06 | -2.34 | -1.27 | -1.10 | -0.58 | -1.91 | -1.22 | -1.29 | -2.28 | -1.79 | -2.01 | -2.36 |
Last Updated: August 20, 2025, 2:50 am
Below is a detailed analysis of the quarterly data for Suven Life Sciences Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 2.00 Cr.. The value appears strong and on an upward trend. It has increased from 1.00 Cr. (Mar 2025) to 2.00 Cr., marking an increase of 1.00 Cr..
- For Expenses, as of Jun 2025, the value is 53.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 45.00 Cr. (Mar 2025) to 53.00 Cr., marking an increase of 8.00 Cr..
- For Operating Profit, as of Jun 2025, the value is -51.00 Cr.. The value appears to be declining and may need further review. It has decreased from -44.00 Cr. (Mar 2025) to -51.00 Cr., marking a decrease of 7.00 Cr..
- For OPM %, as of Jun 2025, the value is -2,714.00%. The value appears strong and on an upward trend. It has increased from -2,981.00% (Mar 2025) to -2,714.00%, marking an increase of 267.00%.
- For Other Income, as of Jun 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.00 Cr..
- For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Jun 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.00 Cr..
- For Profit before tax, as of Jun 2025, the value is -52.00 Cr.. The value appears to be declining and may need further review. It has decreased from -44.00 Cr. (Mar 2025) to -52.00 Cr., marking a decrease of 8.00 Cr..
- For Tax %, as of Jun 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00%.
- For Net Profit, as of Jun 2025, the value is -52.00 Cr.. The value appears to be declining and may need further review. It has decreased from -44.00 Cr. (Mar 2025) to -52.00 Cr., marking a decrease of 8.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is -2.36. The value appears to be declining and may need further review. It has decreased from -2.01 (Mar 2025) to -2.36, marking a decrease of 0.35.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: November 15, 2025, 4:21 am
| Metric | Mar 2008 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 117 | 521 | 499 | 543 | 625 | 286 | 13 | 13 | 12 | 14 | 12 | 7 | 6 |
| Expenses | 105 | 361 | 398 | 414 | 427 | 300 | 128 | 93 | 134 | 139 | 140 | 172 | 219 |
| Operating Profit | 13 | 159 | 102 | 129 | 198 | -14 | -116 | -80 | -122 | -126 | -128 | -166 | -214 |
| OPM % | 11% | 31% | 20% | 24% | 32% | -5% | -917% | -593% | -1,032% | -929% | -1,094% | -2,487% | -3,638% |
| Other Income | 3 | 9 | 19 | 21 | 23 | 27 | 14 | 8 | 5 | 14 | 29 | 11 | 7 |
| Interest | 5 | 5 | 6 | 6 | 5 | 2 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Depreciation | 4 | 12 | 18 | 21 | 21 | 11 | 4 | 4 | 4 | 7 | 6 | 6 | 6 |
| Profit before tax | 6 | 152 | 98 | 123 | 196 | 0 | -106 | -77 | -122 | -118 | -106 | -161 | -212 |
| Tax % | -32% | 28% | 26% | 29% | 37% | 15,038% | -11% | -7% | 0% | 0% | -1% | 0% | |
| Net Profit | 8 | 109 | 72 | 87 | 124 | -24 | -94 | -72 | -122 | -118 | -105 | -161 | -212 |
| EPS in Rs | 0.48 | 5.70 | 3.76 | 4.57 | 6.48 | -1.25 | -4.94 | -3.78 | -5.59 | -5.42 | -4.82 | -7.37 | -9.56 |
| Dividend Payout % | 35% | 7% | 35% | 15% | 15% | -80% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -33.94% | 20.83% | 42.53% | -119.35% | -291.67% | 23.40% | -69.44% | 3.28% | 11.02% | -53.33% |
| Change in YoY Net Profit Growth (%) | 0.00% | 54.78% | 21.70% | -161.88% | -172.31% | 315.07% | -92.85% | 72.72% | 7.74% | -64.35% |
Suven Life Sciences Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 10 years from 2015-2016 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -35% |
| 5 Years: | -12% |
| 3 Years: | -17% |
| TTM: | -16% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -24% |
| 3 Years: | -12% |
| TTM: | -58% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 32% |
| 5 Years: | 36% |
| 3 Years: | 43% |
| 1 Year: | 40% |
| Return on Equity | |
|---|---|
| 10 Years: | -13% |
| 5 Years: | -62% |
| 3 Years: | -55% |
| Last Year: | -87% |
Last Updated: September 5, 2025, 1:41 pm
Balance Sheet
Last Updated: June 16, 2025, 11:16 am
| Month | Mar 2008 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 12 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 15 | 22 | 22 | 22 |
| Reserves | 95 | 547 | 583 | 654 | 755 | 226 | 131 | 95 | 82 | 354 | 248 | 88 |
| Borrowings | 55 | 109 | 83 | 71 | 34 | 3 | 6 | 5 | 3 | 2 | 1 | 0 |
| Other Liabilities | 38 | 105 | 74 | 78 | 118 | 62 | 33 | 16 | 9 | 12 | 14 | 25 |
| Total Liabilities | 199 | 773 | 751 | 816 | 919 | 303 | 182 | 128 | 108 | 389 | 285 | 135 |
| Fixed Assets | 110 | 172 | 305 | 306 | 308 | 22 | 25 | 21 | 38 | 37 | 28 | 60 |
| CWIP | 4 | 107 | 7 | 10 | 25 | 0 | 0 | 5 | 4 | 0 | 0 | 0 |
| Investments | 2 | 0 | 0 | 301 | 279 | 223 | 0 | 0 | 45 | 46 | 76 | 22 |
| Other Assets | 83 | 494 | 439 | 199 | 308 | 58 | 157 | 103 | 22 | 305 | 181 | 53 |
| Total Assets | 199 | 773 | 751 | 816 | 919 | 303 | 182 | 128 | 108 | 389 | 285 | 135 |
Below is a detailed analysis of the balance sheet data for Suven Life Sciences Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 22.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 22.00 Cr..
- For Reserves, as of Mar 2025, the value is 88.00 Cr.. The value appears to be declining and may need further review. It has decreased from 248.00 Cr. (Mar 2024) to 88.00 Cr., marking a decrease of 160.00 Cr..
- For Borrowings, as of Mar 2025, the value is 0.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 1.00 Cr. (Mar 2024) to 0.00 Cr., marking a decrease of 1.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 25.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 14.00 Cr. (Mar 2024) to 25.00 Cr., marking an increase of 11.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 135.00 Cr.. The value appears to be improving (decreasing). It has decreased from 285.00 Cr. (Mar 2024) to 135.00 Cr., marking a decrease of 150.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 60.00 Cr.. The value appears strong and on an upward trend. It has increased from 28.00 Cr. (Mar 2024) to 60.00 Cr., marking an increase of 32.00 Cr..
- For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Investments, as of Mar 2025, the value is 22.00 Cr.. The value appears to be declining and may need further review. It has decreased from 76.00 Cr. (Mar 2024) to 22.00 Cr., marking a decrease of 54.00 Cr..
- For Other Assets, as of Mar 2025, the value is 53.00 Cr.. The value appears to be declining and may need further review. It has decreased from 181.00 Cr. (Mar 2024) to 53.00 Cr., marking a decrease of 128.00 Cr..
- For Total Assets, as of Mar 2025, the value is 135.00 Cr.. The value appears to be declining and may need further review. It has decreased from 285.00 Cr. (Mar 2024) to 135.00 Cr., marking a decrease of 150.00 Cr..
Notably, the Reserves (88.00 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2008 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2008 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -42.00 | 50.00 | 19.00 | 58.00 | 164.00 | -17.00 | -122.00 | -85.00 | -125.00 | -128.00 | -129.00 | -166.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2008 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 111 | 28 | 39 | 31 | 36 | 3 | 66 | 48 | 40 | 22 | 40 | 73 |
| Inventory Days | 200 | 165 | 183 | 222 | 329 | 0 | ||||||
| Days Payable | 157 | 89 | 78 | 91 | 134 | |||||||
| Cash Conversion Cycle | 154 | 105 | 144 | 162 | 231 | 3 | 66 | 48 | 40 | 22 | 40 | 73 |
| Working Capital Days | 139 | 49 | 55 | 42 | 82 | 23 | 704 | 1,084 | 234 | 265 | 101 | -440 |
| ROCE % | 8% | 13% | 15% | 24% | -4% | -54% | -58% | -118% | -53% | -36% | -87% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Motilal Oswal S&P BSE Healthcare ETF | 694 | 0.06 | 0.01 | 694 | 2025-04-22 17:25:19 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | -7.37 | -4.82 | -6.63 | -9.57 | -5.67 |
| Diluted EPS (Rs.) | -7.37 | -4.82 | -6.63 | -9.57 | -5.67 |
| Cash EPS (Rs.) | -7.10 | -4.52 | -5.12 | -8.09 | -5.33 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 5.04 | 12.38 | 17.21 | 6.61 | 8.49 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 5.04 | 12.38 | 17.21 | 6.61 | 8.49 |
| Revenue From Operations / Share (Rs.) | 0.30 | 0.53 | 0.62 | 0.81 | 1.06 |
| PBDIT / Share (Rs.) | -7.10 | -4.90 | -5.39 | -8.05 | -5.68 |
| PBIT / Share (Rs.) | -7.37 | -5.20 | -5.69 | -8.35 | -6.02 |
| PBT / Share (Rs.) | -7.37 | -4.86 | -5.42 | -8.39 | -6.09 |
| Net Profit / Share (Rs.) | -7.37 | -4.82 | -5.42 | -8.39 | -5.67 |
| NP After MI And SOA / Share (Rs.) | -7.37 | -4.82 | -5.42 | -8.39 | -5.67 |
| PBDIT Margin (%) | -2326.94 | -914.01 | -867.37 | -988.42 | -536.50 |
| PBIT Margin (%) | -2414.41 | -969.62 | -915.70 | -1025.51 | -568.75 |
| PBT Margin (%) | -2415.11 | -907.20 | -873.52 | -1029.98 | -574.80 |
| Net Profit Margin (%) | -2415.11 | -898.63 | -873.52 | -1029.98 | -535.31 |
| NP After MI And SOA Margin (%) | -2415.11 | -898.63 | -873.52 | -1029.98 | -535.31 |
| Return on Networth / Equity (%) | -146.14 | -38.91 | -31.51 | -126.88 | -66.80 |
| Return on Capital Employeed (%) | -143.86 | -41.77 | -32.81 | -121.80 | -68.13 |
| Return On Assets (%) | -118.90 | -36.88 | -30.41 | -112.92 | -56.18 |
| Total Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
| Asset Turnover Ratio (%) | 0.03 | 0.03 | 0.02 | 0.03 | 0.04 |
| Current Ratio (X) | 3.21 | 18.99 | 22.61 | 8.01 | 6.45 |
| Quick Ratio (X) | 3.20 | 18.94 | 22.61 | 8.01 | 6.45 |
| Inventory Turnover Ratio (X) | 14.07 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | -3323.53 | -674.71 | -406.21 | -220.85 | -88.68 |
| Interest Coverage Ratio (Post Tax) (X) | -3448.46 | -709.43 | -428.84 | -229.14 | -87.49 |
| Enterprise Value (Cr.) | 2435.23 | 2010.22 | 872.72 | 1343.38 | 849.81 |
| EV / Net Operating Revenue (X) | 365.88 | 171.92 | 64.46 | 113.42 | 63.05 |
| EV / EBITDA (X) | -15.72 | -18.81 | -7.43 | -11.47 | -11.75 |
| MarketCap / Net Operating Revenue (X) | 371.55 | 185.94 | 78.07 | 113.85 | 66.48 |
| Price / BV (X) | 22.48 | 8.05 | 2.82 | 14.02 | 8.30 |
| Price / Net Operating Revenue (X) | 371.56 | 185.97 | 78.08 | 113.85 | 66.48 |
| EarningsYield | -0.06 | -0.04 | -0.11 | -0.09 | -0.08 |
After reviewing the key financial ratios for Suven Life Sciences Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -7.37. This value is below the healthy minimum of 5. It has decreased from -4.82 (Mar 24) to -7.37, marking a decrease of 2.55.
- For Diluted EPS (Rs.), as of Mar 25, the value is -7.37. This value is below the healthy minimum of 5. It has decreased from -4.82 (Mar 24) to -7.37, marking a decrease of 2.55.
- For Cash EPS (Rs.), as of Mar 25, the value is -7.10. This value is below the healthy minimum of 3. It has decreased from -4.52 (Mar 24) to -7.10, marking a decrease of 2.58.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 5.04. It has decreased from 12.38 (Mar 24) to 5.04, marking a decrease of 7.34.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 5.04. It has decreased from 12.38 (Mar 24) to 5.04, marking a decrease of 7.34.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 0.30. It has decreased from 0.53 (Mar 24) to 0.30, marking a decrease of 0.23.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -7.10. This value is below the healthy minimum of 2. It has decreased from -4.90 (Mar 24) to -7.10, marking a decrease of 2.20.
- For PBIT / Share (Rs.), as of Mar 25, the value is -7.37. This value is below the healthy minimum of 0. It has decreased from -5.20 (Mar 24) to -7.37, marking a decrease of 2.17.
- For PBT / Share (Rs.), as of Mar 25, the value is -7.37. This value is below the healthy minimum of 0. It has decreased from -4.86 (Mar 24) to -7.37, marking a decrease of 2.51.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -7.37. This value is below the healthy minimum of 2. It has decreased from -4.82 (Mar 24) to -7.37, marking a decrease of 2.55.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -7.37. This value is below the healthy minimum of 2. It has decreased from -4.82 (Mar 24) to -7.37, marking a decrease of 2.55.
- For PBDIT Margin (%), as of Mar 25, the value is -2,326.94. This value is below the healthy minimum of 10. It has decreased from -914.01 (Mar 24) to -2,326.94, marking a decrease of 1,412.93.
- For PBIT Margin (%), as of Mar 25, the value is -2,414.41. This value is below the healthy minimum of 10. It has decreased from -969.62 (Mar 24) to -2,414.41, marking a decrease of 1,444.79.
- For PBT Margin (%), as of Mar 25, the value is -2,415.11. This value is below the healthy minimum of 10. It has decreased from -907.20 (Mar 24) to -2,415.11, marking a decrease of 1,507.91.
- For Net Profit Margin (%), as of Mar 25, the value is -2,415.11. This value is below the healthy minimum of 5. It has decreased from -898.63 (Mar 24) to -2,415.11, marking a decrease of 1,516.48.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is -2,415.11. This value is below the healthy minimum of 8. It has decreased from -898.63 (Mar 24) to -2,415.11, marking a decrease of 1,516.48.
- For Return on Networth / Equity (%), as of Mar 25, the value is -146.14. This value is below the healthy minimum of 15. It has decreased from -38.91 (Mar 24) to -146.14, marking a decrease of 107.23.
- For Return on Capital Employeed (%), as of Mar 25, the value is -143.86. This value is below the healthy minimum of 10. It has decreased from -41.77 (Mar 24) to -143.86, marking a decrease of 102.09.
- For Return On Assets (%), as of Mar 25, the value is -118.90. This value is below the healthy minimum of 5. It has decreased from -36.88 (Mar 24) to -118.90, marking a decrease of 82.02.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.03. There is no change compared to the previous period (Mar 24) which recorded 0.03.
- For Current Ratio (X), as of Mar 25, the value is 3.21. This value exceeds the healthy maximum of 3. It has decreased from 18.99 (Mar 24) to 3.21, marking a decrease of 15.78.
- For Quick Ratio (X), as of Mar 25, the value is 3.20. This value exceeds the healthy maximum of 2. It has decreased from 18.94 (Mar 24) to 3.20, marking a decrease of 15.74.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 14.07. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 14.07, marking an increase of 14.07.
- For Interest Coverage Ratio (X), as of Mar 25, the value is -3,323.53. This value is below the healthy minimum of 3. It has decreased from -674.71 (Mar 24) to -3,323.53, marking a decrease of 2,648.82.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -3,448.46. This value is below the healthy minimum of 3. It has decreased from -709.43 (Mar 24) to -3,448.46, marking a decrease of 2,739.03.
- For Enterprise Value (Cr.), as of Mar 25, the value is 2,435.23. It has increased from 2,010.22 (Mar 24) to 2,435.23, marking an increase of 425.01.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 365.88. This value exceeds the healthy maximum of 3. It has increased from 171.92 (Mar 24) to 365.88, marking an increase of 193.96.
- For EV / EBITDA (X), as of Mar 25, the value is -15.72. This value is below the healthy minimum of 5. It has increased from -18.81 (Mar 24) to -15.72, marking an increase of 3.09.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 371.55. This value exceeds the healthy maximum of 3. It has increased from 185.94 (Mar 24) to 371.55, marking an increase of 185.61.
- For Price / BV (X), as of Mar 25, the value is 22.48. This value exceeds the healthy maximum of 3. It has increased from 8.05 (Mar 24) to 22.48, marking an increase of 14.43.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 371.56. This value exceeds the healthy maximum of 3. It has increased from 185.97 (Mar 24) to 371.56, marking an increase of 185.59.
- For EarningsYield, as of Mar 25, the value is -0.06. This value is below the healthy minimum of 5. It has decreased from -0.04 (Mar 24) to -0.06, marking a decrease of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Suven Life Sciences Ltd:
- Net Profit Margin: -2415.11%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -143.86% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -146.14% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -3448.46
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 3.2
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 52.67)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -2415.11%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 215 Atrium, C Wing, 8th Floor, Mumbai Maharashtra 400093 | info@suvenpharm.com http://www.suvenpharm.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Vivek Sharma | Executive Chairman |
| Dr. V Prasada Raju | Managing Director |
| Mr. Pankaj Patwari | Non Executive Director |
| Ms. Shweta Jalan | Non Executive Director |
| Mr. Vinod Padikkal | Non Executive Director |
| Mr. Vinod Rao | Independent Director |
| Mr. K G Ananthakrishnan | Independent Director |
| Mr. U B Pravin Rao | Independent Director |
| Ms. Matangi Gowrishankar | Independent Director |
| Mr. Jai Shankar Krishnan | Independent Director |
FAQ
What is the intrinsic value of Suven Life Sciences Ltd?
Suven Life Sciences Ltd's intrinsic value (as of 27 November 2025) is 132.35 which is 24.80% lower the current market price of 176.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 4,018 Cr. market cap, FY2025-2026 high/low of 303/102, reserves of ₹88 Cr, and liabilities of 135 Cr.
What is the Market Cap of Suven Life Sciences Ltd?
The Market Cap of Suven Life Sciences Ltd is 4,018 Cr..
What is the current Stock Price of Suven Life Sciences Ltd as on 27 November 2025?
The current stock price of Suven Life Sciences Ltd as on 27 November 2025 is 176.
What is the High / Low of Suven Life Sciences Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Suven Life Sciences Ltd stocks is 303/102.
What is the Stock P/E of Suven Life Sciences Ltd?
The Stock P/E of Suven Life Sciences Ltd is .
What is the Book Value of Suven Life Sciences Ltd?
The Book Value of Suven Life Sciences Ltd is 12.4.
What is the Dividend Yield of Suven Life Sciences Ltd?
The Dividend Yield of Suven Life Sciences Ltd is 0.00 %.
What is the ROCE of Suven Life Sciences Ltd?
The ROCE of Suven Life Sciences Ltd is 87.0 %.
What is the ROE of Suven Life Sciences Ltd?
The ROE of Suven Life Sciences Ltd is 87.2 %.
What is the Face Value of Suven Life Sciences Ltd?
The Face Value of Suven Life Sciences Ltd is 1.00.